BioSpace News Archive

Cocrystal Pharma, Inc., announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988.

Vaccinex, Inc. announces a new publication in the journal mAbs describing a novel way in which its proprietary ActivMAb® poxvirus platform can enable the presentation of high complexity, hard-to-drug proteins as targets for antibody discovery.

Gradalis, Inc. announced the peer-reviewed publication in Oncology Reviews, a Frontiers Open Access Journal, highlighting Vigil activity in ovarian cancer related to clonal neoantigen expression and the HRP molecular profile.

OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, announced the appointment of Abid Ansari as Chief Financial Officer, effective immediately.

Theriva Biologics announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Emerging Growth Conference, to be held virtually from October 4-5, 2023.

Baudax Bio, Inc., a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, announced that U.S. Food and Drug Administration has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors.

Bionano Genomics, Inc. announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis.

Harbinger Health, a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, announced that it raised $140 million in Series B funding.

ProfoundBio announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan and PRO1160, at the Society for Immunotherapy of Cancer 38th Annual Meeting, to be held at the San Diego Convention Center and virtually November 1-5, 2023.

ARTHEx Biotech S.L. announced that it will present at Chardan’s 7th Annual Genetic Medicines Conference.